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Abstract 1 
The relaxivity displayed by Gd3+ chelates immobilized onto gold nanoparticles is 2 
the result of complex interplay between nanoparticle size, water exchange rate and 3 
chelate structure. In this work we study the effect of the length of ω-thioalkyl linkers, 4 
anchoring fast water exchanging Gd3+ chelates onto gold nanoparticles, on the relaxivity 5 
of the immobilized chelates. Gold nanoparticles functionalized with Gd3+ chelates of   6 
mercaptoundecanoyl and lipoyl amide conjugates of the DO3A-N-(α-amino)propionate 7 
chelator were prepared and studied as potential CA for MRI. High relaxivities per 8 
chelate, of the order of magnitude 28-38 mM-1s-1 (30 MHz, 25 ºC) were attained thanks 9 
to simultaneous optimization of the rotational correlation time and of the water 10 
exchange rate. Fast local rotational motions of the immobilized chelates around 11 
connecting linkers (internal flexibility) still limit the attainable relaxivity. The degree of 12 
internal flexibility of the immobilized chelates seems not to be correlated with the 13 
length of the connecting linkers. Biodistribution and MRI studies in mice suggest that 14 
the in vivo behavior of the gold nanoparticles is determined mainly by size. Small 15 
nanoparticles (HD= 3.9 nm) undergo fast renal clearance and avoidance of the RES 16 
organs while larger nanoparticles (HD= 4.8 nm) undergo predominantly hepatobiliary 17 
excretion. High relaxivities, allied to chelate and nanoparticle stability and fast renal 18 
clearance in vivo suggests that functionalized gold nanoparticles hold great potential for 19 
further investigation as MRI Contrast Agents. This study contributes to understand the 20 
effect of linker length on the relaxivity of gold nanoparticles functionalized with Gd3+ 21 
complexes. It is a relevant contribution towards “design rules” for nanostructures 22 
functionalized with Gd3+ chelates as Contrast Agents for MRI and multimodal imaging.    23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
 31 
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Introduction 1 
MRI is becoming the “central imaging modality” in clinical diagnostic.1 MRI is based 2 
on the nuclear magnetic resonance phenomenon (NMR). In MRI scans, essentially, the 3 
relaxation times (T1 and T2) of the water protons of tissues (intrinsically different) are 4 
acquired and reconstructed into tridimensional anatomical images.2, 3 MRI is inherently 5 
non-invasive, makes use of (benign) non-ionizing radiation (static and radiofrequency 6 
magnetic fields), is depth independent and displays superb spatial resolution. Low 7 
detection sensitivity (inherent to the NMR phenomenon) is the main limitation of MRI.4 8 
Contrast Agents (CA) are paramagnetic species (Gd3+, Mn2+, Fe3+, stable organic 9 
radicals, iron oxide nanoparticles, etc.) that by promoting  selective reduction of T1 or T2 10 
of the water protons of tissues can generate dramatic contrast enhancements.5,6 The 11 
selective enhancement of the relaxation rates, R1,2, (R1,2 = 1/T1,2), normalized to 1 mM 12 
concentration of paramagnetic centres - relaxivity (r1,2, units mM
-1 s-1), measures CA 13 
efficacy.4,7 Approved CA for clinical MRI are either Gd3+ complexes with linear 14 
(DTPA-type) and macrocyclic (DOTA-type) poly(aminocarboxylate) ligands (T1-15 
weighed MRI)8 or iron oxide nanoparticles (IONPS) stabilized with dextran (T2-T2*-16 
weighed MRI).9 Low molecular weight Gd3+-based CA display relaxivities of the order 17 
of magnitude 3-5 mM-1 s-1 at magnetic fields relevant (currently) for clinical MRI (20-18 
120 MHz). The Solomon-Bloembergen-Morgan (SBM) theory predicts that very high 19 
relaxivities, of the order of magnitude 100 mM-1 s-1 at magnetic fields relevant for 20 
clinical imaging (20-120 MHz), are attainable by Gd3+ chelates displaying simultaneous 21 
optimization of the main parameters that govern relaxivity: rotational correlation times 22 
(τR), water exchange rate constant (kex) and electron relaxation parameters (τv and ∆
2).4,7 23 
Despite great advancements in the design and synthesis of CA during the past two 24 
decades, the ideal CA- displaying very high relaxivity and safety in vivo, targeting 25 
capability and responsiveness coupled to therapeutic properties, is still elusive.10 26 
The “nanotechnology revolution” is underway with a dramatic impact in many 27 
fields, particularly in medical imaging.11 Gold nanostructures (nanoparticles, 28 
nanoclusters, nanorods, etc) are finding many applications in chemistry, medicine, 29 
biotechnology and other fields,  owing to intrinsic reporting properties (localized 30 
surface plasmon resonance, fluorescence, X-Ray attenuation)12 coupled to therapeutic 31 
properties (hyperthermia, X-ray sensitization),13 biocompatibility and safety in vivo14 32 
and facile preparation with tunable size and surface properties by bottom-up 33 
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methodologies.15 The first generation of gold nanoparticles (AuNPs) CA made use of, 1 
easy to synthesize, thiol-functionalised Gd(DTPA-bis-amide)16-18 and Gd(DO3A)-type 2 
chelates.19 Superb relaxivities (per nanoparticle) were attained thanks to chelate 3 
clustering.16 In vivo MRI studies established the merits of AuNPs as CA for MRI, 4 
bimodal MRI/X-ray imaging and as theragnostics (MRI/X-ray sensitization).16-18,20 5 
Slow water exchange and fast local rotational motions of the immobilized chelates 6 
around linkers/spacers (chelate flexibility) result in relaxivity enhancements (per 7 
chelate) lower than those expected for Gd3+ chelates appended to rigid nanosized 8 
objects.16-18,21,22 Helm and co-workers reported very high relaxivity per chelate 9 
immobilized onto AuNPs (60 mM-1 s-1; 30 MHz, 25 ºC), attributed to two exchanging 10 
inner sphere water molecules in Gd(DTTA)-type chelates and complete rigidity of the 11 
chelates immobilized via a short aromatic linker.23 The relaxivity was however, still 12 
limited by slow water exchange. We have demonstrated in previous studies that the 13 
Gd[DO3A-N-(α-amino)propionate] chelate and Gd3+ complexes of amide conjugates of 14 
the DO3A-N-(α-amino)propionate chelator display water exchange rates within the 15 
range considered ideal for attaining high relaxivities at intermediate fields, thanks to 16 
“steric compression around the water binding site”.24,25,26 AuNPs functionalized with the 17 
fast water exchanging chelate Gd[DO3A-N-(α-cystamido)propionate] display high 18 
relaxivities at intermediate and high fields (27 and 8.0 mM-1 s-1; 20 and 200 MHz, 19 
respectively, 25 ºC) as the result of simultaneous optimization of the rotational 20 
dynamics and water exchange rate.27 Fast local rotational motions around the cysteine 21 
linker still limit the attainable relaxivity, as demonstrated before for other 22 
macromolecular/nanosized objects such as micelles, dendrimers, polymers, etc.26,27,28 In 23 
this work we address the effect of the length of the ω-thioalkyl linker, anchoring fast 24 
water exchanging Gd[DO3A-N-(α-amido)propionate] chelates to gold nanoparticles, on 25 
the relaxivity. Biodistribution and in vivo MRI studies with the functionalized AuNPs as 26 
CA are reported also.  27 
 28 
 29 
 30 
 31 
 32 
 33 
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Synthesis and characterization 1 
 2 
Mercaptoundecanoyl and lipoyl conjugates of the DO3A-N-(α-amino)propionate 3 
chelator were synthesized to study the effect of the length of the ω-thioalkyl linker on 4 
the relaxivity of AuNPs functionalized with Gd3+ chelates  (Scheme1).  5 
 6 
Scheme 1. Synthetic pathway for ω-thioalkyl conjugates of the DO3A-N-(α-amino)propionate chelator: 7 
a) K2CO3/MeCN;  b) ethyl bromoacetate, K2CO3/MeCN; c) i. TFA/CH2Cl2, ii. DIPEA/CH2Cl2, lipoic 8 
acid, DCC/HOBt; d) i) TFA/DCM, ii. Ethyl bromoacetate, K2CO3/MeCN; e) i. NaOH aq., ii. Flash 9 
chromatography silica gel, iii. SEM (Sephadex G10); f) GdCl3.6H2O; g) i. HAuCl4, NaBH4, ii. 10 
GdCl3.6H2O, iii. SEM (Sephadex G10) followed by dialysis (cellulose tubing MWCO 10 KDa).     11 
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The lipoic acid conjugate (L1) was prepared following the synthetic 1 
methodology reported before for the cysteine conjugate of the DO3A-N-(α-2 
amino)propionate chelator (L3).
27 The synthetic pathway excludes, all along, acidic 3 
conditions likely to promote oligomerization of the chelator through the lipoic acid 4 
moiety.29 Deprotection of the fully alkylated orthogonally protected intermediate 6 5 
allows direct conjugation of lipoic acid to the preformed DO3A-N-α-(amino)propionate 6 
scaffold.27 For preparing the 11-mercaptoundecanoyl conjugate (L2) the preformed 7 
amide was introduced into the cyclen scaffold via Michael addition of the N-Boc,N-(11-8 
(acetylthio)undecanoyl)dehydroalanine methyl ester electrophile (3).25,26 Reactive block 9 
3 was prepared over 3 steps in 48 % overall yield (Scheme 2).30  10 
 11 
Scheme 2. Synthetic route for Michael electrophile N-Boc,N-(11-(acetylthio)undecanoyl)dehydroalanine 12 
methyl ester (3): a) acetic anhydride/pyridine; b) serine methyl ester hydrochloride, HOBt/DCC/NEt3; c) 13 
Boc2O/DMAP, dry acetonitrile. 14 
 15 
The thioacetyl protecting group proved easy to install and stable under mild 16 
alkaline and strong acidic conditions en route to L2. Final deprotection was performed 17 
in one step by saponification with ethanolic NaOH. Following pH adjustment to 18 
neutrality with diluted hydrochloric acid, chelators L1 and L2 were adsorbed onto silica 19 
and purified by flash chromatography followed by Size Exclusion Chromatography 20 
(SEC) on Sepahdex G10 with water elution.  21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
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 1 
Relaxometric studies of GdL1 and GdL2 2 
 3 
The concentration dependence of the paramagnetic longitudinal water proton relaxation 4 
rate (R1p) was measured for GdL1 and GdL2 (20 MHz, 25 ºC, pH 7.1) (Figure 1). 5 
 6 
  7 
Figure 1. Concentration dependence of the paramagnetic water proton relaxation rate R1p = (R1obs-R1d) for 8 
GdL1 (■) and GdL2 (●) (20 MHz, 25 ºC, pH 7.1).  9 
 10 
The relaxation rate data for GdL1 can be well fitted to a straight line (Equation 1) 11 
affording a relaxivity of 8.6±0.9 mM-1 s-1 (20 MHz, 25 ºC, pH 7.1), characteristic of  12 
low/intermediate molecular weight chelates in fast rotation in solution. Fitting the 13 
relaxation rate data of GdL2 requires two straight lines with different slopes (Equation 1 14 
and 2). The concentration at the interception of the two lines defines the critical micelle 15 
concentration- cmc (cmc = 1.5 ± 0.3 mM).31 16 
 
17 
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R1
obs is the longitudinal relaxation rate measured for the solution, R1
d is the 21 
diamagnetic contribution to the longitudinal relaxation rate (the relaxation rate of pure 22 
water) and CGd is the analytical Gd
3+ concentration. 23 
Below the cmc GdL2 is present in solution as monomers (non-aggregated), 24 
displaying a relaxivity (r1
na = 6.6 ± 0.1 mM-1 s-1; 20 MHz, 25 ºC, pH 7.1) characteristic 25 
of low molecular weight chelates (Equation 1).  26 
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For GdL2 at concentrations above the cmc the relaxation rate has a contribution 1 
from monomers (at a concentration equal to the cmc value) and from the (aggregated) 2 
micellar form (r1
a= 15.1 ± 0.8 mM-1 s-1; 20 MHz, 25 ºC, pH 7.1) (Eq. 2). Self-association 3 
of GdL2 into micelle-type structures leads to an increase of the effective molecular 4 
volume of the chelate. Slow tumbling in solution (longer rotational correlation times) 5 
translates into substantially higher relaxivity for the aggregated form of GdL2 6 
comparing to its monomeric (non-aggregated) form. The relaxivity enhancement for 7 
GdL2 upon self-assembly is of the same order of magnitude as that reported for the 8 
DOTA-type Gd(DOTASA-C12) chelate functionalized with a C12 alkyl chain (r1
a = 18.0 9 
mM-1 s-1, 20 MHz, 25 ºC)32, but significantly lower than that attained by the aggregated 10 
form of the fast water exchanging Gd[DO3A-N-(α-pyrenebutanamido)propionate] 11 
chelate (GdL4 in Scheme 1) (r1
a = 32 mM-1 s-1; 20 MHz; 25 ºC).26 The temperature 12 
dependence of the water proton longitudinal relaxation rate for GdL1 and GdL2 (20 13 
MHz, 25 ºC) (Figure SI1) indicates that the relaxivity is not limited by slow water 14 
exchange, as demonstrated before for other Gd3+ chelates of amide conjugates of the 15 
DO3A-N-(α-amino)propionate chelator.24,27   As both GdL2 and Gd[DO3A-N-(α-16 
pyrenebutanamido)propionate] chelates display fast water exchange, the lower 17 
relaxivity attained by GdL2 has to be ascribed to higher internal flexibility and/or 18 
smaller size of the GdL2 micelles (Figure SI2). The pH dependence of the proton 19 
relaxation rate (Figure SI3) and the transmetallation study  (Figure SI4) show that GdL1 20 
and GdL2 are stable in the physiological pH range and kinetically inert towards 21 
transmetallation against Zn2+.33 22 
 23 
Preparation of gold nanoparticles functionalized with GdL1 and GdL2 chelates 24 
 25 
A modified Brust´s methodology in aqueous solution was employed for preparing 26 
AuNPs functionalized with GdL1 and GdL2 chelates.
27,34 Using directly the GdL1 and 27 
GdL2 chelates as nanoparticle stabilizers resulted in extensive precipitation upon 28 
addition of the reducing agent (NaBH4). Attempts to functionalize citrate-stabilized 29 
AuNPs with GdL1 and GdL2 chelates via place exchange revealed also unsuccessful.
18 30 
A two-step methodology, using the L1 and L2 chelators as NPs stabilizers, followed by 31 
Gd3+ complexation, revealed successful for preparing AuNPs functionalized with GdL1 32 
and GdL2 chelates (Scheme 1).
27 
33 
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Solutions containing equimolar amounts of L1 or L2 and HAuCl4 turned 1 
immediately dark brown upon addition, in one aliquot, of one molar equivalent of 2 
NaBH4. Adding a molar equivalent of Gd
3+, in relation to the total amount of L1 or L2 in 3 
the crude mixture, resulted in stable NPs. Size Exclusion Chromatography (SEC) 4 
(Sephadex G10, elution with water) followed by extensive dialysis against water 5 
(cellulose tubing MWCO 10 000), afforded stable AuNPs functionalized with GdL1 and 6 
GdL2 chelates. A single fraction, including the broad colored band eluting on SEC, was 7 
collected. The absence of (free) uncomplexed Gd3+ was confirmed by the xylenol 8 
orange test.35  9 
 10 
Characterization of GdL1@AuNPs and GdL2@AuNPs preparations 11 
 12 
The Gd content of the functionalized AuNPs was estimated by bulk magnetic 13 
susceptibility measurements36 and further confirmed by ICP-OES following sample 14 
digestion with aqua regia (HCl/HNO3; 3/1 v/v) (Table 1).
27,37 15 
The AuNPs were characterized regarding size distribution by Dynamic Light Scattering 16 
(DLS) (Figure 2) and Transmission Electron Microscopy (TEM) (Figure 3). 17 
 18 
 19 
 20 
Figure 2. Size distribution (% volume) for GdL1@AuNPs (A) and GdL2@AuNPs (B).  21 
 22 
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Figure 3. Transmission Electron Microscopy (TEM) for GdL1@AuNPs (A) and GdL2@AuNPs (B).  1 
 2 
DLS measurements give the hydrodynamic diameter (HD) of NPs, including the 3 
Au nanocrystal core, the chelate monolayer and the immobile ionic layer surrounding 4 
the NPs. An average HD of 4.8 nm (NPs distribution in the range 3-10 nm with a 5 
maximum at 3-4 nm) and 5.9 nm (NPs distribution in the range 2-11 nm with a 6 
maximum at 4-5 nm), was measured for GdL1@AuNps and GdL2@AuNPs, 7 
respectively. TEM measurements reveal only the nanocrystal core. The TEM images 8 
obtained for GdL1@AuNPs and GdL2@AuNPs do not allow to determine the average 9 
diameter of the Au core owing to the very small size of the NPs. From the TEM images 10 
one can only conclude that most GdL1@AuNPs and GdL2@AuNPs have a nanocrystal 11 
core with a diameter under 2 nm. The average diameter of the Au core of 12 
GdL1@AuNPs and GdL2@AuNPs (~ 1.0 and 0.9 nm, respectively) was estimated from 13 
the DLS measurements taking into account the thickness of the chelate monolayer, 14 
calculated by PM6 semi-empirical calculations for the most likely conformations of 15 
GdL1 and GdL2 bonded to one or two Au atoms (1.9 and 2.5 nm, respectively) (Figure 16 
SI5, Table SI2).23,24 The absence of a well-defined plasmon absorption band in the UV-17 
Vis spectra of GdL1@AuNPs and GdL2@AuNPs (Figure SI6 and SI7), corroborates the 18 
very small size of the NPs core.38  19 
 20 
 21 
 22 
A B 
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Table 1. Characterization of GdL1@AuNPs and GdL2@AuNPs 1 
 GdL1@AuNPs
a GdL2@AuNPs
a
 GdL3@AuNPs
b 
[Gd] (mM)
c 0.57  1.30  1.24 
 HD (nm)
d
 4.8 5.9 3.9 
Zeta potential (mV) -6.3 -13,7 -12.3 
DAu
e 1.0  0.9 0.7f 
aThis work; bRef 27; cDetermined by ICP-OES; dDLS measurements; eEstimated from the HD and semi-
empirical calculations of the chelate monolayer thicknes- see Table SI2; f Revised value according to semi-
empirical calculations for the length of GdL3. 
 2 
As L1, L2 and L3 share the same coordination cage, the length of the linker 3 
defines the overall wedge-like geometry of the chelator. Shorter linkers originate bulkier 4 
thiol ligands. Ligand bulkiness increases in the series L3>L1>L2 (Figure SI5). Bulkier 5 
thiols are likely to terminate the growth of AuNPs earlier than less bulky ligands, 6 
resulting in AuNPs displaying smaller Au cores associated to higher surface curvature.39 7 
This correlation (DAu = 1.0, 0.9 and 0.7 nm, for GdL1, GdL2 and GdL3@AuNPs) is 8 
followed roughly by L2 and L3. The discrepancy observed for L1 can be due to the 9 
different sulfur binding mode.  10 
GdL1@AuNPs and GdL2@AuNPs were found to be stable in solution for 11 
extended periods. The NPs could be freeze-dried and re-dissolved without 12 
aggregation/precipitation. This can be ascribed to the overall negative charge (-1) of the 13 
immobilized Gd3+ complexes, resulting in NPs displaying negative zeta-potential 14 
(Figure SI8).  15 
 16 
Relaxometric characterization of GdL1@AuNPs and GdL2@AuNPs 17 
 18 
The concentration dependence of the proton longitudinal relaxation rate (R1p) 19 
was evaluated for GdL1@AuNPs and GdL2@AuNPs (r1 = 29 and 38 mM
-1 s-1, 20 
respectively, 20 MHz, 25 ºC, pH 7.1) (Figure SI9).  21 
For relevant clinical applications chelates immobilized onto NPs must be stable 22 
regarding demetallation and inert towards transmetallation with physiological metal 23 
ions, mainly Zn2+.33  In addition to releasing toxic Gd3+, demetallation and 24 
transmetallation processes of immobilized chelates are likely to trigger particle 25 
aggregation and precipitation in vivo. Stability at low pH is particularly important as 26 
protonation-assisted mechanisms have been implicated in demetallation, presumably 27 
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followed by transmetallation with serum ions, of macrocyclic Gd(DOTA)-type 1 
chelates.33,40,41 The pH dependence of the protonic relaxation rate (R1p) was evaluated 2 
for GdL1@AuNPs and GdL2@AuNPs in the pH range 3-10 (Figure SI10).  3 
The kinetic stability of the immobilized chelates (and entire nanoparticles) was 4 
evaluated by challenging GdL1@AuNPs and GdL2@AuNPs with Zn
2+ ions in 5 
phosphate buffer (Figure SI11 and Figure SI12).33 According to the criteria set by 6 
Muller and co-workers, the immobilized chelates (and whole NPs) can be classified as 7 
kinetically inert and thermodynamically stable.33 The pH stability and kinetic inertness 8 
indicate that the NPs are potentially safe for in vivo applications. 9 
 10 
Nuclear Magnetic Relaxation Dispersion Profiles  11 
  12 
The magnetic field dependence of the proton relaxivity (r1) (Nuclear Magnetic 13 
Relaxation Dispersion - NMRD profiles) was obtained for GdL1@AuNPs and 14 
GdL2@AuNPs in the Larmor frequency range 0.01-400 MHz. The most important 15 
parameters that govern relaxivity are the hydration number (q), the water exchange rate 16 
constant (kex), the rotational correlation time (τR) and the electron relaxation parameters 17 
(τv and ∆
2).4,7 The number of water molecules in the first coordination sphere, the water 18 
exchange rate and the rotational correlation time can be tuned by chelate design. Clear 19 
rules to tune the electron relaxation parameters are still elusive.42 Treating chelates 20 
immobilised onto macromolecular/nanosized objects (micelles, proteins, polymers, 21 
dendrimers, nanoparticles, viral particles) as rigid entities, often fails to deliver reliable 22 
parameters from the fitting of the NMRD profiles to the SBM theory. In fact, it is 23 
necessary to assume in the fittings that the interactions that generate the relaxation are 24 
influenced by both fast local rotational motions (τRlocal) of the immobilized chelates 25 
around linkers/spacers and a slower, global motion, common to the entire object 26 
(τRglobal). The degree of spatial restriction of the local motion (interpreted as chelate 27 
flexibility), is measured by the generalized, model independent order parameter- S2. The 28 
order parameter can assume values in the range 0-1: S2= 0 if the internal motions are 29 
isotropic, S2= 1 if the internal motions are completely restricted.43 30 
In this work, it was assumed in the fittings that the immobilised GdL1 and GdL2 31 
complexes have one inner sphere water molecule (q = 1) like other Gd3+ complexes of 32 
the DO3A-N-(α-amino/amido)propionate family.
24-26 The water exchange rate constant 33 
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and its activation enthalpy (kex
298, ∆H‡) were fixed to values determined for the 1 
analogous Gd[(DO3A-N-(α-benzoylamido)propionate] chelate.25  2 
The fittings (continuous lines in Figure 4) are restricted to frequencies above 6 3 
MHz as the SBM theory is not suitable for describing the rotational dynamics of slow-4 
rotating objects at low magnetic fields. The best fit parameters for GdL1@AuNPs and 5 
GdL2@AuNPs, obtained from the analysis of 
1H NMRD data, are represented in Figure 6 
4 and summarized in Table 2. 7 
 8 
 9 
Figure 4.  
1H Nuclear Magnetic Relaxation Dispersion (NMRD) profiles for: A- GdL1@AuNPs (0.56 10 
mM; pH 7.0) 25 °C (■) and 37 °C (●); B- GdL2@AuNPs (1.30 mM; pH 7.0); 25 °C (○) and 37 °C (□). 11 
The fitted curves are represented as continuous lines. The broken lines are the result of simulations using 12 
the same parameters as in Table 2, but assuming total rigidity (S2= 1) of the immobilized chelates.  13 
 14 
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Table 2. Best fit parameters obtained for GdL1@AuNPs and GdL2@AuNPs from the fitting of the 
1H 1 
NMRD profiles to the SMB theory, including the Lipari-Szabo approach for internal flexibility. 2 
 3 
 GdL1@AuNPs GdL2@AuNPs 
Parameters Value Value 
q 1 1 
∆H
‡ [J/mol] 17 17 
kex
298 [107 s-1] 5.14 5.14 
ER [kJ/mol] (global) 19.4±1.1 18±3.6 
τRH
298[ps] (global) 1900±140 3500±940 
ER [kJ/mol] (local) 20 18 
τRH
298[ps] (local) 460±50 970±230 
S2 0.41 ± 0.04 0.42±0.12 
EV [kJ/mol] 1 1 
τV
298 [ps] 27±4 17± 3 
EH
298 [10-10 m2 s-1]  23 23 
EDGH [kJ/mol] 20 20 
Gd-O [Å] 2.5 2.5 
∆
2 [1020 s-2]  0.044±0.002 0.065±0.004 
Gd-HW 1st [Å] 3.1 3.1 
Gd-HW 2nd [Å] 3.6 3.6 
 4 
Table 3. Selected molecular parameters for GdL1@AuNPs and GdL2@AuNPs and other systems 5 
reported in the literature and discussed in the manuscript. 6 
 7 
 8 
The NMRD profiles are characteristic of macromolecular objects in slow 9 
rotation, confirming the immobilization of the GdL1 and GdL2 chelates onto gold 10 
Parameter GdL1@AuNPs
a 
GdL2@AuNPs
a 
GdL3@AuNPs
b
 GdL4
c
 
q 1 1 1 1 
kex
298 [107 s-1] 5.14 5.14 5.14 6.2  
τg
298 [ps] 1900  3500 2470  3780 
τlo
298 [ps] 460  970 177  930 
S
2
 0.41 0.42 0.48  0.24 
HD (nm)d 4.8 5.9 3.9 49e 
r1  (mM 
-1 s-1) 
 27f,h 
 
38f,h 
 
28f,h 
 
32g,h 
11.2f,i 8.4f,i 
 
8.5f,i n.d. 
a This work; bRef 27; 
cRef 26; d From DLS measurements; eZ-average from a bimodal distribution of  particles; f 
Relaxivity per chelate; g Relaxivity of the aggregated form; h 20 MHz, 25 ºC; i  200 MHz, 37 ºC. 
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nanocrystals: a plateau in the frequency range 0.01 to 1 MHz, a simple dispersion at 1 
about 1-10 MHz and a broad hump centered at 20-60 MHz.  2 
The AuNPs prepared in this work display exceptional relaxivities (per Gd3+ 3 
chelate) (r1max = 27 and 38 mM
-1 s-1 for GdL1@AuNPs and GdL2@AuNPs, respectively; 4 
30 MHz, 25 ºC), much higher than those reported by other authors for AuNPs 5 
functionalized with monoaquated (q = 1) Gd3+ complexes.16,19,21 The temperature 6 
dependence of the relaxivity, higher relaxivity at lower temperature, for both 7 
GdL1@AuNPs and GdL2@AuNPs, indicates that the water exchange rate is not limiting 8 
the relaxivity. The superb relaxivities attained can be ascribed to simultaneous 9 
optimization of the water exchange rate (fast water exchange regime) and of the 10 
rotational correlation time. The value obtained for the order parameter (S2 ~ 0.40) 11 
indicates that fast local motions of the chelates anchored onto the Au core are still 12 
limiting the relaxivity. Simulations, using the same parameters as on Table 3, but 13 
assuming total rigidity of the immobilized chelates (S2 = 1), afford much higher 14 
relaxivities (of the order of magnitude 60 mM-1 s-1; 20 MHz; 25 ºC) for GdL2@AuNPs. 15 
The higher relaxivity attained by GdL2@AuNPs, comparing to GdL1@AuNPs and 16 
GdL3@AuNPs, has to be ascribed to its significantly larger global rotational correlation 17 
time (τRg), reflecting the larger size (hydrodynamic diameter) of the GdL2@AuNPs 18 
nanoparticles. In fact, the length of the thioalkyl linker seems not to have much 19 
influence on the internal flexibility of the immobilized chelates: the order parameter S2 20 
is identical for GdL1@AuNPs and GdL2@AuNPs, despite the longer linker anchoring 21 
GdL2 to the Au core. Moreover, the shorter cysteine linker anchoring GdL3 to the Au 22 
core (possibly in a bidentate (N, S) fashion similar to GdL1 (S,S)), results only in 23 
slightly higher rigidity of the immobilized chelates. Despite the limiting effect of the 24 
internal rotational motions, chelate immobilization onto AuNPs results in relaxivity 25 
enhancements of more than 300% for GdL1 and over 500% for GdL2 (comparing to its 26 
monomeric form), attributed to simultaneous optimization of τR and kex. Moreover, 27 
GdL2 immobilized onto AuNPs displays substantially higher relaxivity than the 28 
aggregated (micellar) form of GdL2 (38 vs 15 mM
-1 s-1; 20 MHz, 25 ºC).  The micellar 29 
form of the Gd[DO3A-N-(α-pyrenebutanamido)propionate] chelate (GdL4) (sharing the 30 
same coordination cage with GdL1,2,3) is significantly more flexible (S
2= 0.24 vs 0.42) 31 
than the Au-anchored GdL1 and GdL2 chelates. Accordingly, GdL2@AuNPs, displaying 32 
a τRg value similar to the aggregated form of  GdL4, exhibits higher relaxivity (38 vs 32 33 
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mM-1 s-1; 20 MHz, 25 ºC, for GdL2@AuNPs and for the aggregated form of GdL4, 1 
respectively).26 2 
Covalent immobilization of Gd3+ chelates onto AuNPs seems more effective in 3 
attaining high relaxivities, than chelate self-assembly into micelle-type structures, 4 
owing to higher restriction of internal rotational motions.  5 
The work reported here addresses explicitly the effect of linker length on the 6 
relaxivity of AuNPs functionalized with Gd3+ chelates, contributing to the “rational 7 
design” of nanomaterials as CA for MRI/multimodal imaging.44 8 
 9 
Biodistribution studies  10 
The biodistribution of [153Sm]L1@AuNPs in Wistar rats was obtained at 2 and 24 hours 11 
post-injection (Figure 6). 12 
 13 
 14 
Figure 6. Biodistribution of [153Sm3+]L1@AuNPs in Wistar rats, stated as percent of injected dose per 15 
gram of organ (% ID/ g): a) 2 and b) 24 hour post-injection. Inset - time evolution of the activity in the 16 
blood. The results are from a group of four animals in each experiment. 17 
 
18 
The activity in the blood was measured after 30 minutes, 60 minutes, 2 and 24 
19 
hours (inset in Figure 6) revealing fast clearance of activity from the blood with a 
20 
reduction of approximately 50% between 30 minutes and two hours. After 2 hours post-
21 
injection, the NPs are mainly found in the organs of the reticulo-endothelial system 
22 
(RES), liver and spleen, and to a lesser extent in the blood and lungs. These results 
23 
suggest that the nanoparticles are cleared mainly by phagocytosis by the macrophage 
24 
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rich organs, liver and spleen, with a less important contribution from renal 
1 
elimination.20,26,45 This is in accordance with what was found by MRI for 
2 
GdL1@AuNPs (see below). 
3 
At 24 hours post-injection significant activity is found only in the organs of the 4 
reticulo-endothelial system, RES. The activity approximately doubled in the spleen, 5 
showing only a slight increase in the liver. The activity in the bones at 24 hours post-6 
injection is very low, suggesting that the rate of chelate demetallation and formation of 7 
insoluble metal colloids in vivo is very low.  8 
 9 
MRI Studies 
10 
 
11 
MRI studies were performed in male Swiss mice (~ 20 g) in a preclinical 
12 
imaging platform (PharmaScan) operating at 7.0 Tesla (300 MHz). A Dynamic Contrast 
13 
Enhancement (DCE) study was performed with GdL1@AuNPs (0.1 mmol Gd/kg body 
14 
weight) and GdL3@AuNPs (0.1 and 0.05 mmol Gd/kg body weight) and for 
15 
comparison purposes with Gd(DTPA) (Magnetvist®, Bayer) at the same doses (Figure 
16 
7). Figure 7 shows a representative series of T1-weighted spin-echo coronal images. In 
17 
the pre-injection images, the kidney structures (cortex, inner and outer medulla) and 
18 
adjacent tissues appear dark. After bolus injection in the vascular system, a strong signal 
19 
enhancement was observed in the kidneys for Gd(DTPA), GdL1@AuNPs and 
20 
GdL3@AuNPs as result of T1 shortening. A much slighter signal enhancement was 
21 
observed in the liver. Both NPs follow mainly renal elimination by glomerular filtration, 
22 
with significant hepatobiliary contribution to excretion seen for GdL1@AuNPs only.  
23 
  
24 
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 1 
 2 
Figure 7. Representative coronal T1-weighted spin echo MR images of mice before and after injection of 3 
contrast agents: (A) Gd(DTPA) (0.1 mmol Gd kg-1 BW), (B) GdL1@AuNPs (0.1 mmol Gd kg
-1 BW), (C) 4 
GdL3@AuNPs (0.1 mmol Gd kg
-1 BW); (D) Gd(DTPA) (0.05 mmol Gd kg-1 BW), (E) GdL3@AuNPs 5 
(0.05 mmol Gd kg-1 BW). 6 
 7 
The time course of the average intensity (mean values of groups of four animals) 8 
within different regions of interest (ROIs) placed on the several organs (Figure 8) 9 
allows to understand better the features of Figure 7. 10 
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 1 
 2 
Figure 8. Time course of signal intensity, up to 60 min post-injection,  for several regions of interest, 3 
relative to the initial value, during dynamic contrast enhancement MRI experiments in rats administrated 4 
with: (A) Gd(DTPA) (0.1 mmol kg-1 BW) and (B) GdL1@AuNPs (0.1 mmol kg
-1 BW), (C) 5 
GdL3@AuNPs (0.1 mmol kg
-1 BW); (D) Gd(DTPA) (0.05 mmol kg-1 BW); (E) GdL3@AuNPs (0.05 6 
mmol kg-1 BW). The time courses are data from mean values of four animals. 7 
 8 
In order to compare the results for all the animals under study (n = 4), the data 9 
were normalized by calculating the mean relative enhancement of each ROI. The 10 
scattering in the time course curves was caused by animal respiratory motion. The 11 
relative enhancement obtained with Gd(DTPA) at 0.1 mmol kg-1 BW dose (Figure 8A), 12 
increased almost immediately after intravenous injection, from 0 up to about 160% in 13 
the kidney medulla and 100% in the kidney cortex, followed by a steady decrease to 14 
values around 60% and 30%, respectively, within 60 minutes. This time course is in 15 
agreement with the literature for the Gd(DTPA) and Gd(DOTA) low molecular weight 16 
CA.46,47 17 
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The enhancement profiles of GdL1@AuNPs (Figure 8B) and GdL3@AuNPs 1 
(Figure 8C) at 0.1 mol Gd kg-1 BW dose are considerably different from the 2 
enhancement profile of Gd(DTPA) at the same concentration: there is an immediate 3 
enhancement of the kidney structures (cortex and medulla) followed by a steady liver 4 
enhancement. For GdL3@AuNPs at 0.1 mmol Gd kg
-1 BW dose (Figure 8C) is 5 
noticeable a fast and strong enhancement of the kidney medulla and kidney cortex (~ 6 
150%) which slowly decreases to ~100% over the time course of the experiment. A 7 
much lower muscle and liver enhancement is also noticeable. Reducing the dose of 8 
GdL3@AuNPs to 0.05 mmol Gd Kg
-1 BW results in an imaging profile virtually 9 
equivalent to Gd(DTPA): fast renal elimination with negligible hepatobiliary 10 
contribution (Figure 8D and 8E for Gd(DTPA) and GdL3@AuNPs, respectively). There 11 
is a fast enhancement of the kidney cortex (~150 % at 20 minutes) which steadily 12 
decreases over the time course of the experiment.  These results strongly suggest that 13 
while GdL1@AuNPs is mostly eliminated through hepatobiliary excretion, or is taken 14 
up by resident macrophages (Kupfer cells) in liver, GdL3@AuNPs behaves in vivo as a 15 
low molecular weight CA following mainly renal elimination. The steady, liver and 16 
presumably spleen enhancement observed with GdL1@AuNPs is in sharp contrast to 17 
the “clean” renal elimination observed for GdL3@AuNPs. This behaviour can only be 18 
explained by the difference in size between GdL1@AuNPs and GdL3@AuNPs- average 19 
HD 4.8 and 3.9 nm, respectively, stressing the complex interplay between the physical-20 
chemical properties of nanostructures and in vivo behaviour.  21 
The animal MRI studies were performed at high field (300 MHz, 7 Tesla). This study 22 
illustrates the mismatch between the performance of macromolecular/nanosized CA, 23 
optimized for intermediate fields (20-60 MHz), and the trend for increasingly higher 24 
magnetic field imagers. The overwhelming advantage of the AuNPs, over low 25 
molecular weight CA at intermediate fields (20-60 MHz), is partially eroded at higher 26 
magnetic fields (Figure 4).48 Nonetheless, the AuNPs studied in this work still exhibit 27 
relaxivities significantly higher than Gd(DTPA) at high fields (11.2, 8.4 vs ~ 2 mM-1 s-1 28 
for GdL1@AuNPs and GdL2@AuNPs, respectively, and Gd(DTPA), 200 MHz, 25 ºC ). 29 
 30 
 31 
 32 
 33 
 34 
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Conclusions 1 
  In this work we extend the synthetic methodologies developed before for AuNPs 2 
functionalized with stable fast water exchanging Gd3+ chelates as high relaxivity, 3 
potentially safe CA for in vivo MRI. Two novel ligands were designed to investigate the 4 
role of the length of the ω-thioalkyl linker, anchoring the coordination cage to the gold 5 
nanocrystal, on the relaxivity. Superb relaxivities at magnetic fields relevant for clinical 6 
imaging (27 and 38 mM-1 s-1, 30 MHz, 25 ºC, for GdL1@AuNPs and GdL2@AuNPs, 7 
respectively) were obtained attained thanks to simultaneous optimization of the 8 
rotational correlation time and of the water exchange rate. Relaxivities, still relevant for 9 
clinical high field applications (of the order of magnitude 10 mM-1 s-1; 200 MHz, 37 ºC) 10 
were attained also. The relaxivity is still limited by internal flexibility of the 11 
immobilized chelates. The degree of internal flexibility of the immobilized chelates 12 
(measured by the order parameter S2) seems not to be determined by the length of the 13 
linker, presumably owing to the high surface curvature of the NPs. A MRI study in mice 14 
demonstrated that while GdL3@AuNPs (HD = 3.9 nm) behaves in vivo much like the 15 
low molecular weight CA Gd(DTPA), undergoing fast renal elimination without liver 16 
(and presumably spleen) uptake, GdL1@AuNPs (HD = 4.8 nm) shows considerable 17 
hepatobiliary contribution to elimination. A biodistribution study in rats using the 18 
surrogate 153SmL1@AuNPs tracer confirmed extensive activity uptake and 19 
accumulation over time in the liver and spleen.  20 
The GdL3@AuNPs CA, amenable to further elaboration with targeting moieties, 21 
seems particularly promising for in vivo MRI applications. 22 
The work reported is a relevant contribution towards the design of nanomaterials 23 
functionalized with Gd3+ chelates as very high relaxivity/multimodal CA for MRI.44 24 
   25 
 26 
  27 
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Experimental  1 
Materials and methods 2 
  3 
Chemicals were purchased from Sigma-Aldrich and used without further purification. 4 
Cyclen was purchased from Chematech, France. Analytical grade solvents were used 5 
and not further purified, unless specified. Reactions were monitored by TLC on silica 6 
gel by examination under UV light (250 and 365 nm) and staining with iodine vapour 7 
and Ellman´s reagent. Preparative chromatography was carried out on Silica Gel 60 8 
(230-400 mesh). Ion exchange chromatography was performed on Dowex 1X2-100-9 
OH- (50-100 mesh) resin. Size Exclusion Chromatography (SEC) was performed on 10 
Sephadex G10 (40-120 µm) with water elution. Dialysis was performed against water 11 
on cellulose membranes (MWCO 10 KDa). UV-VIS spectra were acquired with a 12 
Shimadzu UV-2501PC spectrophotometer. The size distribution and zeta potential of 13 
the AuNPs was determined with a Malvern Zetasizer, NANO ZS (Malvern Instruments 14 
Limited, UK), using a He-Ne laser (wavelength of 633 nm) and a detector angle of 173º. 15 
TEM experiments were performed with a JEOL JEM1200EXII microscope at Bath 16 
University, UK. Mass spectrometry was performed at CACTI - Vigo, Spain.  17 
1H and 13C NMR spectra were run on Varian Unity Plus 300, Bruker Avance-3 18 
400 Plus and Varian VNMRS 600 NMR spectrometers. Chemical shifts (δ) are given in 19 
ppm relative to the CDCl3 solvent (
1H, δ 7.27; 13C 77.36) as internal standard. For 1H 20 
and 13C NMR spectra recorded in D2O, chemical shifts (δ) are given in ppm, relative to 21 
TSP as internal reference (1H, δ 0.0) and tert-butanol as external reference (13C, CH3 δ 22 
30.29), respectively.  23 
 24 
Preparation of Lipoic acid conjugate DO3A-N-(α-lipoamido)propionate - L1 25 
 26 
Synthesis of ((5-(1,2-dithiolan-3-yl)-2-pentanamido)methoxycarbonylethyl)-4,7,10-27 
tris-(ethoxycarbonylmethyl) -1,4,7,10-tetraazacyclododecane - fully protected 28 
conjugate 7. 29 
Orthogonally protected compound 6 was synthesized as described before by us.27 A 30 
solution of compound 6 (85 mg; 1.12 mmol) in a mixture DCM/TFA (24 ml, 3:1, v/v) 31 
was stirred at room overnight. The solvent was removed under reduced pressure, the 32 
residue was re-dissolved in DCM and the solvent was evaporated. This procedure was 33 
repeated several times.  34 
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The resulting oil was dried under vacuum to afford a white foam. 1H NMR (CDCl3) 1 
revealed the disappearance of the signals assigned to the Boc groups on compound 6. 2 
Quantitative deprotection was assumed. The residue (1.12 mmol, assuming quantitative 3 
deprotection) was dissolved in DCM (20 ml) and the solution was adjusted to pH 9-10 4 
(pH paper) by drop-wise addition of DIPEA. To this solution was added sequentially 5 
Lipoic acid (288 mg; 1.40 mmol), HOBt (214 mg; 1.40 mmol) and a solution of DCC 6 
(288 mg; 1.40 mmol) in DCM (5 ml). The solution was stirred at room temperature 7 
overnight. The DCU byproduct was removed by filtration and the reaction mixture was 8 
concentrated under reduced pressure. The residue was re-dissolved in ethyl acetate (100 9 
ml), and the solution was washed with NaHCO3 (50 ml, saturated solution) and brine 10 
(3x50 ml). The organic phase was dried (MgSO4) and concentrated under reduced 11 
pressure to afford the title compound (7) (358 mg; 44 %). 1H NMR (300 MHz, CDCl3): 12 
δ= 1.28 (m, 9 H, C(O)OCH2CH3), 1.48 (m, 2 H, NHC(O)CH2CH2CH2), 1.70 (m, 2 H, 13 
NHC(O)CH2CH2), 2.18 (m, 2 H, NHC(O)CH2CH2CH2CH2), 2.30 (m, 4 H, NHC(O)CH2 14 
and CHCH2CH2S), 2.60-3.60 (broad overlapped signals, integrating for 16 H, 15 
N(CH2)2N; 2 H, ABX; 2 H, CHCH2CH2S, 1 H, CHSCH2CH2S), 3.73 (m, 6 H, 16 
C(O)CH2N), 3.97 (s, 3 H, C(O)OCH3), 4.19 (m, 6 H, C(O)CH2CH3), 4.90 (dd,1 H, 17 
ABX). HRMS (ESI): m/z: cacd. for C32H58N5O9S2 [M+H]
+: 720.3676, found: 720.3645. 18 
 19 
Preparation of ((5-(1,2-dithiolan-3-yl)-2-pentanamido)carboxyethyl)-4,7,10-tris-20 
(carboxymethyl)-1,4,7,10-tetraazacyclododecane - fully deprotected DO3A-N-(α-21 
lipoamido)propionate chelator (L1). 22 
Compound (7) (2.26 g, 3.15 mmol) was dissolved in a mixture water/ethanol (40 ml, 1/1 23 
v/v). The solution was adjusted to pH ~ 11 with aqueous NaOH 1 M (pH paper) and 24 
was left stirring at room temperature overnight. Then, the reaction mixture was adjusted 25 
to pH ~7 with hydrochloric acid 1 M (pH paper) and concentrated under reduced 26 
pressure. The residue was adsorbed onto silica and purified by flash chromatography 27 
(CH2Cl2CH2Cl2/EtOH 1/1EtOHEtOH/H2O 1/1H2O) to afford a light yellow 28 
foam. The final compond (L1) was further purified by size exclusion chromatography 29 
on Sephadex G10 (0.42 µm) with elution with water. The conductivity of the collected 30 
fractions was measured and were also tested by TLC (ethanol/water (1/1), revelation 31 
with iodine vapor). The high conductivity fractions (salt) were discarded and the 32 
medium/low conductivity fractions showing a signal on the TLC were pooled, 33 
concentrated at room temperature and further dried under vacuum to afford the final 34 
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deprotected compound as a light yellow solid (L1) (0.685 g, 35%). 
1H NMR (300 MHz, 1 
D2O): δ= 1.46 (m, J= 7.8 Hz, 2 H, NHC(O)CH2CH2CH2), 1.64-1.72 (m, 6 H, 2 
NHC(O)CH2CH2, NHC(O)CH2CH2CH2CH2, CHCH2CH2S), 2.01 (m, 2 H, 3 
NHC(O)CH2), 2.34 (t, J= 7.5 Hz 2 H, CHCH2CH2S), 2.49 (m, 1 H, CHSCH2CH2S), 4 
2.10-3.40 (broad overlapped signals integrating to 16 H, 4 x N(CH2)2N, 6 H, 3x 5 
NCH2C(O) and 2H, ABX), 4.49 (m, 1 H, ABX). 
13C NMR (75.4 MHz, D2O): 25.02 (1 6 
C, CH2), 28.32 (1 C, CH2), 33.93 (1 C, CH2), 35.73 (1 C, CH2), 38.22 (1 C, CH2), 40.46 7 
(2 C, 2xCH2), 47.81 (3 C, 3xCH2), 49.46 (1 C, CH2), 51.37 (1 C, CHCH2), 51.94 (2 C, 8 
CH2), 54.51 (2 C, CH2), 56.08 (2 C, CH2), 56.76 (2 C, CH2), 170.94 (1 C, C(O), 176.65 9 
(2 C, 2xC(O), 177.36 (2 C, 2xC(O)). HRMS (ESI): m/z: cacd. for C25H44N5O9S2 10 
[M+H]+: 622.2580, found: 622.2572.  11 
 12 
Preparation of  11-mercaptoundecanoic acid conjugate DO3A-N-(α-13 
mercaptoundecanamido)propionate - L2  14 
 15 
Synthesis of 11-(acetylthio)undecanoic acid  (10) 16 
 17 
To an ice-cooled solution of 11-mercaptoundecanoic acid (9) (2.00 g, 9.17 mmol) in 18 
pyridine (2.6 ml) was added acetic anhydride (2.6 ml, 2.81 g, 27.5 mmol). The solution 19 
was left stirring at room temperature overnight.  Ice was directly added to the reaction 20 
mixture, followed by magnetic stirring until complete melting of the ice.  The mixture 21 
was extracted with ethyl acetate (3×150 ml). The organic phase was washed with brine 22 
(3x30 ml), dried (MgSO4) and the solvent was removed under reduced pressure. The 23 
residue was further dried under vacuum to afford the final compound as an off-white 24 
solid (2.12 g, 89%). 1H NMR (400 MHz, CDCl3): δ= 1.27 (s (br),12 H, 6×CH2), 1.58-25 
1.52 (m, 2 H, SCH2CH2), 1.66-1.59 (m, 2 H, (CO2H)CH2CH2), 2.32 (s, 3 H, C(O)CH3), 26 
2.35 (t, J= 7.2 Hz, 2 H, CH2COOH), 2.86 (t, J= 7.2 Hz, 2 H, SCH2). 
13C NMR (100.62 27 
MHz, CDCl3): δ= 24.61 (C(O)CH2CH2), 28.73 (SCH2),  28.97, 29.00, 29.10, 29.13, 28 
29.26, 29.32 (overlapped inner CH2 signals), 29.43 (SCH2CH2), 30.59 (CH3),  33.99 29 
(C(O)CH2),  179.89 (COOH),  196.11 (SC(O)Me). HRMS (ESI): m/z: calcd. for 30 
C13H24NaO3S [M+Na]
+: 283.1338, found.: 283.1339. 31 
 32 
 33 
 34 
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 1 
Synthesis of (11-(acetylthio)undecanoyl)serine methyl ester (11) 2 
 3 
To an ice-cooled solution of compound 10 (2.12 g, 8.14 mmol) in acetonitrile (70 ml) 4 
was added HOBt (1.85 g, 8.95 mmol) and a solution of DCC (1.25 g, 8.14 mmol) in 5 
acetonitrile (10 ml). The mixture was left stirring at the ice bath temperature and after 6 
15 minutes L-serine methyl ester hydrochloride (1.27 g, 8.14 mmol) and triethylamine 7 
(1.13 ml, 0.82 g, 8.14 mmol) were added. The reaction mixture was left stirring at room 8 
temperature overnight. The DCU byproduct was removed by filtration and the sample 9 
was concentrated under reduced pressure. The residue was re-dissolved in ethyl acetate 10 
(100 ml) and the solution was washed sequentially with KHSO4 (1 M, 3x50 ml), 11 
NaHCO3 (saturated solution, 50 ml) and brine (3x50 ml). The organic phase was dried 12 
(MgSO4) and concentrated under reduced pressure to afford title compound 11 (2.73 g; 13 
93%).1H-NMR (CDCl3, 400 MHz): δ= 1,25 (s (br), 12 H, 6 × CH2), 1.52-1.57 (m, 2 H, 14 
SCH2CH2), 1.58-1.65 (m, 2 H, NHC(O)CH2CH2), 2.25 (t, J= 7.2 Hz, 2 H,  15 
NHC(O)CH2), 2.30 (s, 3 H, SC(O)CH3), 2.84 (t, J= 7.2 Hz, 2 H, SCH2), 3.76 (s, 3 H, 16 
OCH3),  3.87 (ddd, J= 3.6, 11.2, 29.8 Hz, 1 H, CHaHbOH), 3.96 (ddd, J= 4.0, 11.0 and 17 
29.8 Hz, 1 H, CHaHbOH),  4.67-4.63 (m, 1 H, CH), 6.62 (s (br), 1 H, NH). 
13C-NMR 18 
(CDCl3, 100.62 MHz): δ= 24.80 (NHC(O)CH2CH2), 28.67, 28.95, 29.06, 29.09 19 
(overlapped CH2 signals), 29.17 (SCH2), 29.25, 29.27 (overlapped CH2 signals), 29.37 20 
(SCH2CH2), 30.55 (SC(O)Me), 36.37 (C(O)CH2), 52.54 (OMe), 54.54 (CH), 63.20 21 
(CH2OH), 171.03 (C(O)OMe), 173.78 (NHC(O)), 196.19 (SC(O)).  22 
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Synthesis of N-(tert-butoxycarbonyl),N-(11-(acetylthio)undecanoyl) 1 
dehydroalanine methyl ester (3) 2 
 3 
To a solution of compound (11) (0.866 g, 2.40 mmol) in dry acetonitrile (15 ml) was 4 
sequentially added DMAP (0.081 g, 0.66 mmol) and Boc2O (1.44 g, 6.6 mmol). The 5 
mixture was left stirring for 5 days at room temperature. The reaction progress was 6 
monitored by 1H NMR. A small volume of reaction mixture was removed, worked-up 7 
was as described below, and analyzed by 1H NMR by monitoring the disappearance of 8 
the  signal of the intermediate carbonate ester and the appearance of the alkenic signals 9 
at δ= 5.62 and 6.44 ppm. The solid residues were removed by filtration and the sample 10 
was concentrated under reduce pressure. The residue was re-dissolved in ethyl acetate 11 
(150 ml), and the solution was washed sequentially with KHSO4 (1 M, 3x50 ml), 12 
NaHCO3 (saturated solution, 50 ml) and brine (3x50 cm
3). The organic phase was 13 
concentrated under reduced pressure and the residue was purified by a flash 14 
chromatography (n-hexane→n-hexane/ethyl acetate  (70:30)) to afford the title 15 
compound as a thick reddish oil (0.445 g, 58%).1H-NMR (CDCl3, 400 MHz) δ= 1.27 (s 16 
(br), 12 H, 6×CH2), 1.46 (s, 9 H, C(CH3)3), 1.49-1.57 (m, 2 H, SCH2CH2), 1.65 (m, 2 H, 17 
C(O)CH2CH2), 2.32 (s, 3 H, SC(O)CH3),  2.86 (t, J= 7.6 Hz, 2 H, NHC(O)CH2), 2.93 18 
(t, J= 7.6 Hz, 2 H, SCH2), 3.78 (s, 3 H, C(O)OCH3),  5.62 (s, 1 H, CCHaHb), 6.44 (s, 1 19 
H, CCHaHb). 
13C-NMR (CDCl3, 100.62 MHz): δ= 24.71 (C(O)CH2CH2), 27.40 20 
(SCH2CH2), 27.80 (3×OCCH3), 28.75, 29.05, 29.08, 29.11, 29.35, 29.44 (overlapped 21 
CH2 signals), 29.38 (C(O)CH2), 30.59 (SC(O)CH3), 37.66 (SCH2), 52.38 (C(O)OCH3), 22 
83.53 (OCCH3), 125.71 (CCH2), 135.56 (CCH2), 151.52 (NC(O)O), 163.68 23 
(C(O)OCH3), 175.66 (NC(O)), 196.00 (SC(O)). HRMS (ESI): m/z: calcd. for 24 
C22H37NaO6S [M+Na]
+: 466.2234, found: 466.2223. 25 
 26 
Synthesis of (11-(acetylthio)-2-N-(tert-butoxycarbonyl)undecanamido-27 
methoxycarbonylethyl)-1,4,7,10-tetraazacyclododecane - monoalkylated cyclen (5) 28 
 29 
To a solution of cyclen (0.260 g, 1.5 mmol) in acetonitrile (30 ml) was added K2CO3 30 
(0.83 g, 6.0 mmol) and in several portions compound 3 (0.445 g, 1.0 mmol). The 31 
suspension was vigorously stirred at room temperature for 4 hours. The suspended solid 32 
was removed by filtration and the solvent was evaporated under reduced pressure.  33 
 34 
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The residue was purified by flash chromatography 1 
(CH2Cl2CH2Cl2/EtOH/NH3/H2O (70:30:5:5)) to the afford the title compound 5 as a 2 
white foam (0.451 g, 73.0 %).1H-NMR (CDCl3, 400 MHz): δ= 1.33 (s (br), 12 H, 3 
6×CH2), 1.47 (s, 9 H, OC(CH3)3), 1.60 (m, 2 H, C(O)CH2CH2), 1.60-1.65 (m, 2 H, 4 
SCH2CH2), 2.33 (s, 3 H, SC(O)CH3), 2.51-2.65 (m, 16 H, 4×N(CH2)2N), 2.74-2.79 (m, 5 
2 H, (NHC(O)CH2)), 2.74-2.79 (m, 1 H, NCHaCHbCH), 2.85 (t, J= 7.2 Hz, 2 H, 6 
CH3C(O)SCH2), 3.45 (dd, J= 5.2 and 14.4 Hz, 1 H, NCHaCHbCH), 3.68 (s, 3 H, 7 
C(O)OCH3), 5.46 (t, J= 5.2 Hz, 1 H, NCH2CH). 
13C-NMR (CDCl3, 100.62 MHz): δ= 8 
25.01 (C(O)CH2CH2), 27.90 (OCCH3), 28.75 (SCH2), 29.05, 29.10, 29.17, 29.37, 29.39, 9 
29.40 (overlapped CH2 signals), 29.43 (SCH2CH2), 30.58 (SC(O)Me), 40.06 10 
(C(O)CH2), 46.92 (6×NHCH2), 51.07 (2×CH2NCH2CH), 52.16 (C(O)OMe), 53.56 11 
(NCH2CH), 58.06 (NCH2CH), 83.99 (C), 151.96 (NC(O)O), 170.84 (C(O)OMe), 12 
175.52 (N(Boc)C(O)CH2), 195.99 (SC(O)). HRMS (ESI): m/z: calcd. for C30H58N5O6S 13 
[M+H]+: 616.4102, found.: 616.4100. 14 
 15 
Synthesis of (11-(acetylthio)-2-undecanamido-methoxycarbonylethyl)-4,7,10-16 
tris-(ethoxycarbonylmethyl)-1,4,7,10-tetraazacyclododecane - fully alkylated cyclen 17 
(8) 18 
 19 
A solution of monoalkylated cyclen 5 (0.451 g, 0.87 mmol) in trifluoroacetic acid in 20 
dichlorometane (33%, 24 ml) was stirred overnight at room temperature. The solvent 21 
was evaporated at reduced pressure and the residue was re-dissolved in dichlorometane. 22 
The solvent was evaporated again, and this procedure was repeated several times to give 23 
a light thick yellow oil which was further dried under vacuum. 1H NMR spectroscopy 24 
(CDCl3) revealed the disappearance of the signal assigned to the Boc group in the 25 
precursor compound 5. The deprotected compound (0.87 mmol, assuming quantitative 26 
deprotection) was re-dissolved in MeCN (20 ml), K2CO3 (1.17 g, 8.46 mmol) was 27 
added and the suspension was left under vigorous stirring at room temperature for 30 28 
minutes. Ethyl bromoacetate (0.29 ml, 2.61 mmol) was added, and the suspension was 29 
further stirred for 2 hours. The suspended solids were removed by filtration, the solvent 30 
was evaporated under reduce pressure and the residue was purified by flash 31 
chromatography (CH2Cl2 CH2Cl2/EtOH (7:3)) to afford compound 8 (0.218 g, 32 %) 32 
as a white foam.  33 
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1H-NMR (CDCl3, 400 MHz): δ= 1.33 (m, 12 H, 6×CH2), 1.47 (s, 9 H, OC(CH3)3), 1.60 1 
(m, 2 H, C(O)CH2CH2), 1.60-1.65 (m, 2 H, SCH2CH2), 2.32 (s, 3 H, SC(O)Me), 2.70-2 
2.90 (m, 16 H, 4×N(CH2)2N), 2.74-2.79 (m, 2 H, (C(O)CH2)), 2.74-2.79 (m, 1 H, 3 
NCHaCHbCH), 2.85 (t, J= 7.2 Hz, 2 H, SCH2), 3.49 (m, 6 H, 3×C(O)CH2CH3 and 1 H, 4 
NCHaCHbCH), 3.72 (s, 3 H, C(O)OCH3), 4.19 (m, 6 H, C(O)OCH2CH3), 5.46 (t, J= 5.2 5 
Hz, 1 H, NCH2CH). HRMS (ESI): m/z: calcd. for C37H68N5O10S [M+H]
+: 774.4681, 6 
found: 774.4684. 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
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Synthesis of (11-mercapto-2-undecanamido-carboxyethyl)-4,7,10-tris-1 
(carboxymethyl)-1,4,7,10-tetraazacyclododecane - Fully deprotected DO3A-N-(α-2 
mercaptoundecanamido)propionate chelator (L2) 3 
Compound 8 (0.218 g, 0.28 mmol) was dissolved in a mixture EtOH/H2O (20 ml, 1:1 4 
(v/v)). The solution was adjusted to pH ~ 10-11 (pH paper) with aqueous NaOH (1 M) 5 
and left stirring at room temperature overnight. The solution was adjusted to pH ~ 7 (pH 6 
paper) with diluted hydrochloric acid (1M) and was evaporated at reduced pressure 7 
(temperature < 40 ºC). The residue was adsorbed onto silica and purified by flash 8 
chromatography (CH2Cl2CH2Cl2/EtOH 1/1EtOHEtOH/H2O 1:1H2O) to afford 9 
a light yellow foam. The residue was re-dissolved in water and was purified by size 10 
exclusion chromatography (Sephadex G10). The relevant fractions were pooled together 11 
and the solvent was removed under reduced pressure to give chelator L2 (0.074 g, 42 12 
%).1H-NMR (CDCl3, 400 MHz): δ= 1.33 (s (br), 10 H, 5×CH2),1.61 (s (br), 2 H, 13 
SCH2CH2CH2), 1.63 (s (br), 2 H, (C(O)CH2CH2), 1.72 (s (br), 2 H, SCH2CH2), 2.33 (s 14 
(br), 2 H, (C(O)CH2), 2.58 (t, J= 6.8 Hz, 2 H, SCH2), 2.80 (s (br), 1 H, NCHaHbCH), 15 
2.80 (s (br), 1 H, NCHaHbCH), 3.18 (s, 4 H, NCH2CH2NCH2CH), 3.39-3.36 (m, 4 H, 16 
N(CH2)2N), 3.43 (s, 8 H, 2×N(CH2)2N), 3.76 (s (br), 6 H, 3×NCH2(C(O)OH), 4.52 (s 17 
(br), 1 H, CH). 13C-NMR (CDCl3, 100.62 MHz): δ= 23.82 (SCH2), 25.13 18 
(C(O)CH2CH2), 27.73 (SCH2CH2), 28.11, 28.31, 28.39, 28.52, 28.61 (overlapped CH2 19 
signals), 33.08 (SCH2CH2CH2), 35.84 (C(O)CH2), 38.51 (NCH2CH), 48.79 (2× 20 
NCH2CH2NCH2CH), 51.20 (CH), 51.62 (2×NCH2CH2NCH2CH), 56.56 (3× 21 
NCH2(C(O)OH), 56.09 (2×NCH2CH2N), 177.14 (NHC(O)), 177.14 (CHC(O)OH), 22 
177.30 (3×NCH2C(O)OH). HRMS (ESI): m/z: calcd for C28H51N5NaO9S [M+Na]
+: 23 
656.3305, found: 656.3300. 24 
 25 
Preparation of GdL1 and GdL2 complexes for relaxometric measurements 26 
 27 
A solution of GdCl3.6H2O was added drop-wise, under magnetic stirring, to an 28 
equimolar solution of L1 or L2 (5% excess), while keeping the solution pH around 5.8 29 
(pH meter) by the addition of diluted NaOH. The solution was left stirring at room 30 
temperature overnight. Then, the solution was adjusted to pH 7.0 with NaOH (0.1 M) 31 
and filtered through a 0.2 µm syringe filter. The absence of free Gd3+ was confirmed by 32 
the xylenol orange test. The final concentration of Gd was determined by ICP-OES 33 
following sample digestion with nitric acid.  34 
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 1 
Preparation gold nanoparticles functionalized with GdL1 and GdL2 chelates. 2 
 3 
An aqueous solution of ligand DO3A-N-(α-Lipoamido)propionate (L1) (20.5 mM, 4.53 4 
ml, 0.091 mmol) was added drop-wise, under magnetic stirring at room temperature, to 5 
an aqueous solution of HAuCl4 (58.86 mM, 1.54 ml, 0.091 mmol). During the initial 6 
stages of the addition of L1, the light yellow HAuCl4 solution turned dark orange, 7 
fading away in color to light yellow with further addition of ligand. To the reaction 8 
mixture was added, in one aliquot, a freshly prepared aqueous NaBH4 solution (522 9 
mM, 0.179 ml, 0.093 mmol). The reaction mixture turned instantaneously dark brown 10 
and was left stirring at room temperature for 16 hours. The NPs solution was adjusted to 11 
pH ~ 7 (pH meter) by adding aqueous NaOH (0.1 M) and was filtered through a 0.20 12 
µm PTFE syringe filter. A small volume of solution (1 ml) was kept for further 13 
characterization. To remaining NPs solution (~ 5.3 ml) was added slowly a solution of 14 
GdCl3.6H2O in water (303 µM, 0.300 ml, 0.091 mmol) while keeping the solution pH 15 
around 5.5 (pH meter) by adding aqueous NaOH 0.1 M. The NPs solution was left 16 
stirring at room temperature for 16 hours and was adjusted to pH ~ 7 with aqueous 17 
NaOH (1 M solution). The nanoparticles were purified by size exclusion 18 
chromatography (Sephadex G10, 0.42 µm) with elution with water. The entire colored 19 
broad band eluting from the column was collected without attempting to fractionate the 20 
sample. The nanoparticles were further purified by extensive dialysis against water 21 
using a 10 KDa MWCO cellulose membrane. The xylenol orange test indicated the 22 
absence of free Gd3+ in the gold nanoparticles preparation. 23 
The same procedure was followed for the preparation of GdL2@AuNPs starting 24 
from ligand L2 (20.5 mg/mL, 2 ml, 0.0647 mmol) and HAuCl4 (22 mg/ml, 1 ml, 0.0647 25 
mmol).  26 
The Gd and Au content of the NPs preparations ([Gd]= 0.57 mM and 1.30 mM; 27 
[Au]/[Gd]= 1.40 and 0.87, for GdL1@AuNPs and GdL2@AuNPs, respectively) was 28 
determined by ICP-OES analysis following sample digestion with aqua regia. 29 
 30 
NMRD measurements 31 
 32 
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The NMD measurements were performed using a StelarSpinmaster FFC NMR 1 
relaxometer (0.01-20 MHz) equipped with a VTC90 temperature control unit. At higher 2 
fields, the 1H relaxivity measurements were performed on Bruker Minispecs mq30 (30 3 
MHz), mq40 (40 MHz) and mq60 (60 MHz), as well as Bruker Advance spectrometers 4 
connected to 2.35 T, 4.7 T and 9.4 T superconducting magnets. In each case, the 5 
temperature was measured by a substitution technique. Variable temperature 6 
measurements were performed at 25 and 37 ◦C. The NMRD profiles were analysed 7 
using the Visualiseur/Optimiseur 3.6 program running on a Matlab® 6.5 platform.49  8 
 9 
Relaxivity studies of pH dependence and Zn
2+ 
transmetallation 10 
 11 
The transmetallation reaction of the GdL1 and GdL2  chelates and of the metal chelate-12 
decorated NPs GdL1@AuNps and GdL2@AuNPs against Zn
2+, was studied by 13 
following the time-dependent decrease of the protonic longitudinal relaxation rate, R1, 14 
(20 MHz, 25 ºC) of phosphate-buffered saline solutions (PBS, pH 7.1, 10 mM), 15 
containing GdL1, GdL2, GdL1@AuNPs and GdL2@AuNPs ([Gd]= 1.0, 1.13, 0.42, 1.33 16 
mM, respectively), before and after adding an equimolar amount of ZnCl2, while 17 
vigorously stirring the solutions. 18 
The pH dependence of the relaxivity was measured by adjusting the solution pH 19 
with aqueous diluted NaOH (0.1 M) or diluted hydrochloric acid (0.1 M), using a 20 
Crison micro TT 2050 pH meter equipped with a Mettler Toledo 422 electrode. A 21 
Bruker Minispec mq20 relaxometer was used for all measurements (20 MHz, 25 ºC). 22 
 23 
MRI studies 24 
 25 
Preparation of the GdL1@AuNPs and GdL2@AuNPs CA solutions for MRI 26 
studies. 27 
 28 
The GdL1@AuNPs and GdL2@AuNPs CA for the MRI studies were prepared 29 
following the procedure described above. The final nanoparticles solutions were freeze-30 
dried and their Gd and Au content (per mg of solid material) were determined by ICP-31 
OES following digestion with aqua regia.  32 
 33 
 34 
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In vivo MRI studies.  1 
 2 
The experimental protocols were approved by the appropriate institutional review 3 
committees and meet the guidelines of their responsible governmental agency. The 4 
Magnetic Resonance Imaging (MRI) experiments were all performed on a Bruker 5 
Pharmascan platform (Bruker Medical GmbH, Ettlingen, Germany) using a 7.0 T (300 6 
MHz) horizontal-bore superconducting magnet, equipped with a 1H selective 60 mm 7 
birdcage resonator and a Bruker gradient insert with 90 mm diameter (maximum 8 
intensity 360 mT/m). Data were acquired using a Hewlett-Packard console running 9 
Paravision software (Bruker Medical Gmbh, Ettlingen, Germany) under a LINUX 10 
environment.  11 
All MRI examinations were carried out on mice (n = 4, ~ 20 g body weight) 12 
anaesthetized initially by inhalation in an induction box with O2 (1 L/min) containing 3 13 
% isoflurane, and maintained during the experiment using a face mask allowing free 14 
breathing and 1-2 % isoflurane on O2. Animals were taped down into a holder, to 15 
minimize breathing - related motion, and were then placed in a heated probe, which 16 
maintained the core body temperature at 37 ± 0.5 °C, monitored by a rectal probe. The 17 
physiological state of the animal was monitored throughout the entire experiment by a 18 
Biotrig physiological monitor (Bruker Medical GmbH, Ettlingen, Germany), using the 19 
respiratory rate and body temperature.  20 
Solutions of GdL1@AuNPs and GdL2@AuNPs 10 mM in [Gd] were prepared 21 
by dissolving the freeze-dryed NPs in the appropriate volume of PBS buffer. The 22 
solutions were filtered through a 0.2 µm seringe filter before injection. 10 mM 23 
Gd(DTPA) (Magnevist, Schering, Berlin, Germany) solutions were also prepared. The 24 
solutions were injected into the catheterized tail vein as a bolus in 20 s (0.05 and 0.1 25 
mmol Gd  kg-1 body weight) using an infusion pump (Panlab, Barcelona, Spain).  26 
Regional contrast agent uptake was assessed using Dynamic Contrast Enhanced 27 
(DCE) MRI. DCE MRI experiments were performed with series of T1-weighted spin 28 
echo images sequentially acquired over 1 h, before and following the injection of the 29 
contrast agent 10 min after the beginning of the study. The acquisition parameters were: 30 
TR = 310 ms, TE = 10.58 ms, number of averages = 2, ten coronal slices, slice thickness 31 
= 2 mm, FOV = 5.0 x 5.0 cm, matrix = 256 x 256, 30 repetitions with a total acquision 32 
time of 119 s.  33 
 34 
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MRI data analysis.  1 
 2 
Data were analyzed with the public domain software Image J (http://rsbweb.nih.gov/ij/). 3 
With the aim of comparing the pharmacokinetics obtained from different animals, the 4 
data were normalized by calculating the percentage of relative, rather than absolute, 5 
enhancement: 6 
   100
)(
0
0 ×
−
=
I
II
RE  7 
where I is the signal intensity at any given time after CA injection and I0 is the intensity 8 
before injection. Pharmacokinetic behaviour was analyzed by calculating the average 9 
enhancements within the different regions of interest (ROIs) placed on each one of the 10 
following regions: liver, kidney medulla, kidney cortex and muscle. 11 
 12 
Biodistribution of radiolabeled nanoparticles 13 
 14 
Preparation of [
153
Sm]L1@AuNPs chelates for the biodistribution studies 15 
 16 
In these studies 153Sm3+ was used as a radioactive surrogate of Gd3+.  [153SmCl3] (1 mCi) 17 
was added to a solution of L1@AuNPs (5 mg freeze-dried NPs) in sodium acetate buffer 18 
(400 µL, 0.4 M, pH 5). The solution was stirred at 80 ºC for 5 hours. After that, cold 19 
SmCl3 was added to each solution in order to obtain an equimolar Sm
3+:chelator ratio. 20 
The final solution was heated at 80 ºC for 2 hours and left overnight at room 21 
temperature. The radiolabeled nanoparticles were purified by size exclusion 22 
chromatography using a Sephadex G-10 column eluted with 0.4 M acetate buffer. The 23 
whole colored broad band eluting from the column was collected and concentrated by 24 
centrifugal filtration (Centricon 10 kDa MWCO membrane, Millipore).   25 
 26 
Biodistribution studies 27 
 28 
Groups of four animals (Wistar rat males weighting ca 200 g) were anaesthetized with 29 
Ketamine (50.0 mg/mL)/chloropromazine (2.5%) (10:3) and injected in the femoral vein 30 
with ca 100 µCi of  [153Sm]L1@AuNPs and sacrificed 2 and 24 hours later. The major 31 
organs were excised, weighed and the tissue radioactivity was measured in a γ well-32 
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counter. Blood samples were obtained at appropriate periods of time, weighted and 1 
radioactivity counted.  2 
National regulations for the care and use of laboratory animals were strictly followed in 3 
this study. 4 
 5 
Semiempirical calculations, molecular modelling and NPs size estimates  6 
 7 
All calculations were performed with Mopac code50 using the semiempirical model 8 
Hamiltonian PM651 and COSMO52 implicit water solvent model (ε= 74.8 with Gd and 9 
Au tesserae radius taken as 0.2 nm). The length of the chelates was estimated from 10 
various chelate conformers averaged over several S…O and S…H top bottom distances 11 
within conformers (Figure SI5); ascribing an error of 0.1 nm to the estimates seems 12 
reasonable for this methodology. The average AuNPs diameter is estimated from the 13 
diameter exclusion of the left and right chelates (Table SI2).   14 
 15 
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